Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 2/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.35 |
| ▸ | HTR6 | P50406 | 4/20 | 0.34 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.34 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15631066 | 0.85 | KMT2A (0.39) | HTR6ALDH1A1KMT2ATOP2AF2 | |
| SCHEMBL9923991 | 0.75 | ALDH1A1 (0.40) | HTR6ALDH1A1KMT2AKDM4EHPGD | |
| SCHEMBL9923898 | 0.74 | ALDH1A1 (0.40) | HTR6KCNK3KCNK9ALDH1A1TOP2A | |
| SCHEMBL9923910 | 0.73 | KDM4E (0.39) | HTR6ALDH1A1KMT2AKDM4EHPGD | |
| SCHEMBL9893234 | 0.72 | NR1H3 (0.34) | CCR5ALDH1A1KDM4EHPGDF2 | |
| SCHEMBL9893254 | 0.71 | MAPT (0.35) | CCR5ALDH1A1KDM4EHPGDF2 | |
| SCHEMBL9924019 | 0.70 | KDM4E (0.43) | KCNK3KCNK9ALDH1A1KMT2ATOP2A | |
| SCHEMBL9924026 | 0.69 | TRPM8 (0.46) | — | |
| SCHEMBL9924024 | 0.69 | TRPM8 (0.54) | — | |
| SCHEMBL9893275 | 0.69 | HSD17B10 (0.46) | ALDH1A1KMT2AKDM4EPKMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067935-B2 | Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2015-06-30 | — | — | US | disclosed |
| US-9067935-B2 | Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2015-06-30 | — | — | US | disclosed |
| US-20140088098-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2014-03-27 | — | — | US | disclosed |
| US-20140088098-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2014-03-27 | — | — | US | disclosed |
| US-8618150-B2 | Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-12-31 | — | — | US | disclosed |
| US-20120149699-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2012-06-14 | — | — | US | disclosed |
| US-20120149699-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149699-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPV1, TRPM2 | CCR5 3492/4885KEAP1 2035/4885NFE2L2 1755/4885 |
| US-20140088098-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPV1, TRPM2 | CCR5 3492/4885KEAP1 2035/4885NFE2L2 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.